A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled, Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effe

Administered By

Surgery, Surgical Sciences

Awarded By

Moderna Therapeutics, Inc.

Contributors

Beerman, Rebecca Clinical Data Manager
Montefiori, David Charles Principal Investigator
Sarzotti-Kelsoe, Marcella Director
Shen, Xiaoying Co Investigator

Start/End

June 1, 2021 - May 31, 2024